Claims
- 1-14. (Cancelled).
- 15. A method of fusing unwanted tumor cells in a human patient, comprising administering to said patient a composition in an amount sufficient to cause fusion of said unwanted tumor cells, wherein said composition comprises a nucleic acid vector and a diluent that does not include culture serum, wherein said nucleic acid vector comprises a nucleotide sequence encoding a measles virus F glycoprotein and a nucleotide sequence encoding a chimeric measles virus H glycoprotein, wherein said measles virus F glycoprotein is expressible on a eukaryotic cell surface, wherein said chimeric measles virus H glycoprotein is expressible on a eukaryotic cell surface, and wherein said composition is directly delivered to said unwanted tumor cells.
- 16. A method of fusing unwanted tumor cells in a human patient, comprising administering to said patient a composition in an amount sufficient to cause fusion of said unwanted tumor cells, wherein said composition comprises a eukaryotic host cell and a diluent which does not include culture serum, wherein said eukaryotic host cell contains a nucleic acid vector comprising a nucleotide sequence encoding a measles virus F glycoprotein and a nucleotide sequence encoding a chimeric measles virus H glycoprotein, wherein said measles virus F glycoprotein is expressed on the surface of said eukaryotic host cell, wherein said chimeric measles virus H glycoprotein is expressed on the surface of said eukaryotic host cell, and wherein said composition is directly delivered to said unwanted tumor cells.
- 17. A method of treating a patient comprising tumor cells, said method comprising administering to said patient a therapeutically effective amount of a composition, wherein said composition comprises a nucleic acid vector and a diluent which does not include culture serum, wherein said nucleic acid vector comprises a nucleotide sequence encoding a measles virus F glycoprotein and a nucleotide sequence encoding a chimeric measles virus H glycoprotein, wherein said measles virus F glycoprotein is expressible on a eukaryotic cell surface, wherein said chimeric measles virus H glycoprotein is expressible on a eukaryotic cell surface, wherein said composition is directly delivered to said tumor cells, and wherein the number of tumor cells is reduced.
- 18. A method of treating a patient comprising tumor cells, said method comprising administering to said patient a therapeutically effective amount of a composition, wherein said composition comprises a eukaryotic host cell and a diluent which does not include culture serum, wherein said eukaryotic host cell contains a nucleic acid vector comprising a nucleotide sequence encoding a measles virus F glycoprotein and a nucleotide sequence encoding a chimeric measles virus H glycoprotein, wherein said measles virus F glycoprotein is expressed on the surface of said eukaryotic host cell, wherein said chimeric measles virus H glycoprotein is expressed on the surface of said eukaryotic host cell, wherein said composition is directly delivered to said tumor cells, and wherein the number of tumor cells is reduced.
Priority Claims (1)
Number |
Date |
Country |
Kind |
GB9705007.4 |
Mar 1997 |
GB |
|
RELATED APPLICATIONS
[0001] This application claims benefit of PCT/GB98/00710, filed Mar. 10, 1998, which claims benefit of U.S. Ser. No. 60/045,164, filed Apr. 30, 1997 and UK 9705007.4, filed Mar. 11, 1997.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60045164 |
Apr 1997 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09070630 |
Apr 1998 |
US |
Child |
10732438 |
Dec 2003 |
US |
Parent |
PCT/GB98/00710 |
Mar 1998 |
US |
Child |
09070630 |
Apr 1998 |
US |